 Mina Pantcheva
Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 18 | 2023 | 204 | 3.980 |
Why?
| | Glaucoma, Open-Angle | 8 | 2023 | 95 | 3.040 |
Why?
| | Ocular Hypertension | 7 | 2022 | 61 | 3.030 |
Why?
| | Intraocular Pressure | 21 | 2023 | 277 | 2.340 |
Why?
| | Phacoemulsification | 8 | 2023 | 107 | 2.180 |
Why?
| | Uveitis | 3 | 2022 | 115 | 2.050 |
Why?
| | Trabeculectomy | 6 | 2022 | 65 | 1.930 |
Why?
| | Laser Coagulation | 4 | 2023 | 54 | 1.380 |
Why?
| | Trabecular Meshwork | 6 | 2022 | 77 | 1.320 |
Why?
| | Visual Acuity | 6 | 2019 | 273 | 1.320 |
Why?
| | Uveitis, Anterior | 2 | 2019 | 11 | 1.300 |
Why?
| | Cataract | 7 | 2023 | 185 | 1.250 |
Why?
| | Cataract Extraction | 4 | 2023 | 76 | 1.160 |
Why?
| | Ciliary Body | 3 | 2018 | 33 | 0.970 |
Why?
| | Endoscopy | 3 | 2018 | 247 | 0.820 |
Why?
| | Fibronectins | 3 | 2021 | 108 | 0.780 |
Why?
| | Chondroitin Sulfates | 2 | 2020 | 33 | 0.750 |
Why?
| | Glycosaminoglycans | 2 | 2022 | 80 | 0.750 |
Why?
| | Retinal Ganglion Cells | 6 | 2022 | 92 | 0.700 |
Why?
| | Corneal Injuries | 3 | 2024 | 34 | 0.670 |
Why?
| | Uveitis, Posterior | 1 | 2019 | 12 | 0.660 |
Why?
| | Tissue Scaffolds | 2 | 2020 | 180 | 0.650 |
Why?
| | Collagen | 2 | 2020 | 415 | 0.640 |
Why?
| | Mustard Gas | 3 | 2024 | 117 | 0.620 |
Why?
| | Chemical Warfare Agents | 3 | 2024 | 121 | 0.620 |
Why?
| | Biocompatible Materials | 2 | 2020 | 379 | 0.580 |
Why?
| | Disease Management | 1 | 2019 | 562 | 0.520 |
Why?
| | Epithelial-Mesenchymal Transition | 4 | 2021 | 168 | 0.490 |
Why?
| | Tomography, Optical Coherence | 2 | 2019 | 128 | 0.470 |
Why?
| | Tonometry, Ocular | 6 | 2021 | 83 | 0.460 |
Why?
| | Lens, Crystalline | 3 | 2021 | 96 | 0.440 |
Why?
| | Prostaglandins F | 1 | 2011 | 17 | 0.400 |
Why?
| | Retrospective Studies | 11 | 2023 | 12616 | 0.360 |
Why?
| | Risk Assessment | 1 | 2019 | 3004 | 0.350 |
Why?
| | Postoperative Complications | 2 | 2022 | 2167 | 0.340 |
Why?
| | Epithelial Cells | 3 | 2021 | 965 | 0.330 |
Why?
| | Capsule Opacification | 2 | 2020 | 20 | 0.330 |
Why?
| | Nerve Fibers | 1 | 2009 | 87 | 0.330 |
Why?
| | Transforming Growth Factor beta2 | 2 | 2021 | 31 | 0.320 |
Why?
| | Humans | 36 | 2024 | 115890 | 0.300 |
Why?
| | Inflammation | 1 | 2018 | 2503 | 0.290 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2007 | 58 | 0.280 |
Why?
| | Eye | 2 | 2006 | 101 | 0.280 |
Why?
| | Stents | 3 | 2021 | 477 | 0.260 |
Why?
| | Cornea | 4 | 2024 | 107 | 0.250 |
Why?
| | Angiogenesis Inhibitors | 2 | 2018 | 216 | 0.250 |
Why?
| | Glaucoma Drainage Implants | 2 | 2021 | 47 | 0.250 |
Why?
| | Postoperative Period | 4 | 2019 | 293 | 0.240 |
Why?
| | Lens Implantation, Intraocular | 3 | 2022 | 57 | 0.230 |
Why?
| | Treatment Outcome | 5 | 2022 | 9165 | 0.230 |
Why?
| | Aged | 12 | 2021 | 19296 | 0.230 |
Why?
| | Macular Edema | 1 | 2023 | 35 | 0.220 |
Why?
| | Iritis | 1 | 2023 | 2 | 0.220 |
Why?
| | Aged, 80 and over | 6 | 2019 | 6437 | 0.220 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2022 | 56 | 0.210 |
Why?
| | Antihypertensive Agents | 2 | 2016 | 430 | 0.200 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2021 | 32 | 0.190 |
Why?
| | Kynurenine 3-Monooxygenase | 1 | 2020 | 3 | 0.180 |
Why?
| | Kynurenic Acid | 1 | 2020 | 10 | 0.180 |
Why?
| | Posterior Capsule of the Lens | 1 | 2020 | 10 | 0.180 |
Why?
| | Animals | 17 | 2024 | 32120 | 0.180 |
Why?
| | Hepatitis C | 1 | 2022 | 229 | 0.170 |
Why?
| | Disease Models, Animal | 5 | 2022 | 3583 | 0.170 |
Why?
| | Ophthalmology | 1 | 2001 | 77 | 0.170 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2020 | 161 | 0.160 |
Why?
| | Prosthesis Implantation | 2 | 2018 | 139 | 0.160 |
Why?
| | Aldehyde Reductase | 1 | 2018 | 24 | 0.160 |
Why?
| | Rabbits | 3 | 2024 | 754 | 0.160 |
Why?
| | Male | 16 | 2021 | 56123 | 0.160 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 16 | 0.150 |
Why?
| | Risk Factors | 3 | 2022 | 8714 | 0.150 |
Why?
| | Dexamethasone | 3 | 2024 | 315 | 0.150 |
Why?
| | Reperfusion Injury | 1 | 2020 | 257 | 0.150 |
Why?
| | Aspirin | 1 | 2020 | 327 | 0.140 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 301 | 0.140 |
Why?
| | Microscopy, Electron, Scanning | 2 | 2007 | 194 | 0.140 |
Why?
| | Stem Cells | 1 | 2001 | 543 | 0.140 |
Why?
| | Middle Aged | 8 | 2023 | 27080 | 0.140 |
Why?
| | Filtering Surgery | 1 | 2016 | 22 | 0.130 |
Why?
| | Perception | 1 | 2018 | 316 | 0.130 |
Why?
| | Crystallins | 1 | 2016 | 41 | 0.130 |
Why?
| | Glaucoma, Neovascular | 1 | 2015 | 10 | 0.130 |
Why?
| | Female | 11 | 2023 | 60076 | 0.130 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 104 | 0.120 |
Why?
| | Histones | 1 | 2020 | 539 | 0.120 |
Why?
| | Enzyme Inhibitors | 1 | 2018 | 758 | 0.120 |
Why?
| | Drug Packaging | 1 | 2015 | 43 | 0.120 |
Why?
| | Actins | 3 | 2024 | 384 | 0.120 |
Why?
| | Patient Preference | 1 | 2016 | 171 | 0.120 |
Why?
| | Caspases | 3 | 2005 | 245 | 0.110 |
Why?
| | Follow-Up Studies | 2 | 2019 | 4446 | 0.110 |
Why?
| | Incidence | 1 | 2019 | 2333 | 0.110 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 616 | 0.100 |
Why?
| | Ophthalmic Solutions | 3 | 2018 | 66 | 0.100 |
Why?
| | Mice | 7 | 2022 | 15073 | 0.100 |
Why?
| | Corneal Edema | 1 | 2010 | 4 | 0.090 |
Why?
| | Descemet Stripping Endothelial Keratoplasty | 1 | 2010 | 7 | 0.090 |
Why?
| | Medication Adherence | 1 | 2015 | 536 | 0.090 |
Why?
| | Swine | 2 | 2016 | 706 | 0.090 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2009 | 36 | 0.080 |
Why?
| | Visual Fields | 1 | 2009 | 76 | 0.080 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 4670 | 0.080 |
Why?
| | Mice, Knockout | 3 | 2020 | 2607 | 0.070 |
Why?
| | Prospective Studies | 4 | 2021 | 6266 | 0.070 |
Why?
| | Sclera | 1 | 2007 | 35 | 0.070 |
Why?
| | Young Adult | 2 | 2019 | 10515 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 1868 | 0.070 |
Why?
| | Intravitreal Injections | 2 | 2018 | 46 | 0.070 |
Why?
| | United States | 2 | 2023 | 12340 | 0.070 |
Why?
| | Adult | 5 | 2019 | 30814 | 0.070 |
Why?
| | Pigment Epithelium of Eye | 1 | 2006 | 34 | 0.070 |
Why?
| | Autopsy | 1 | 2006 | 86 | 0.070 |
Why?
| | Optic Nerve | 1 | 2006 | 65 | 0.070 |
Why?
| | Optic Nerve Injuries | 1 | 2005 | 4 | 0.060 |
Why?
| | Administration, Topical | 2 | 2016 | 137 | 0.060 |
Why?
| | Preoperative Period | 2 | 2019 | 103 | 0.060 |
Why?
| | Caspase Inhibitors | 1 | 2005 | 78 | 0.060 |
Why?
| | Tacrolimus | 1 | 2005 | 143 | 0.060 |
Why?
| | Adolescent | 2 | 2019 | 17949 | 0.060 |
Why?
| | Irritants | 1 | 2024 | 41 | 0.060 |
Why?
| | Mechlorethamine | 1 | 2024 | 64 | 0.060 |
Why?
| | Loteprednol Etabonate | 1 | 2023 | 6 | 0.050 |
Why?
| | Actin Cytoskeleton | 1 | 2024 | 92 | 0.050 |
Why?
| | Photoreceptor Cells, Vertebrate | 1 | 2003 | 25 | 0.050 |
Why?
| | Acetazolamide | 1 | 2023 | 29 | 0.050 |
Why?
| | Triamcinolone Acetonide | 1 | 2023 | 27 | 0.050 |
Why?
| | Axonal Transport | 1 | 2022 | 21 | 0.050 |
Why?
| | Rats | 4 | 2022 | 5035 | 0.050 |
Why?
| | Laminin | 1 | 2022 | 69 | 0.050 |
Why?
| | Neuroprotection | 1 | 2022 | 30 | 0.050 |
Why?
| | Blindness | 1 | 2022 | 37 | 0.050 |
Why?
| | Cell Line | 2 | 2020 | 2655 | 0.050 |
Why?
| | Retinal Detachment | 1 | 2003 | 53 | 0.050 |
Why?
| | Chromatography, Liquid | 1 | 2024 | 346 | 0.050 |
Why?
| | Algorithms | 1 | 2009 | 1493 | 0.050 |
Why?
| | Heat-Shock Proteins | 1 | 2022 | 113 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2022 | 141 | 0.050 |
Why?
| | Ligands | 1 | 2024 | 568 | 0.050 |
Why?
| | Signal Transduction | 3 | 2021 | 4525 | 0.050 |
Why?
| | Intraoperative Complications | 1 | 2022 | 126 | 0.050 |
Why?
| | Tandem Mass Spectrometry | 1 | 2024 | 416 | 0.050 |
Why?
| | Molecular Chaperones | 1 | 2022 | 157 | 0.050 |
Why?
| | Manometry | 1 | 2021 | 88 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2005 | 666 | 0.050 |
Why?
| | Inflammation Mediators | 1 | 2024 | 481 | 0.050 |
Why?
| | Hepacivirus | 1 | 2022 | 234 | 0.050 |
Why?
| | Mice, 129 Strain | 1 | 2020 | 77 | 0.040 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2020 | 88 | 0.040 |
Why?
| | Rats, Inbred BN | 3 | 2005 | 53 | 0.040 |
Why?
| | Circadian Rhythm | 1 | 2023 | 371 | 0.040 |
Why?
| | Caspase 9 | 3 | 2005 | 48 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2020 | 4767 | 0.040 |
Why?
| | Acetylation | 1 | 2020 | 212 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2022 | 439 | 0.040 |
Why?
| | Axial Length, Eye | 1 | 2018 | 9 | 0.040 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 14 | 0.040 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.040 |
Why?
| | Pseudophakia | 1 | 2018 | 11 | 0.040 |
Why?
| | Histological Techniques | 1 | 2018 | 40 | 0.040 |
Why?
| | Refraction, Ocular | 1 | 2018 | 30 | 0.040 |
Why?
| | Proteomics | 1 | 2024 | 854 | 0.040 |
Why?
| | Sleep | 1 | 2023 | 623 | 0.040 |
Why?
| | Enzyme Activation | 3 | 2005 | 791 | 0.040 |
Why?
| | Microscopy | 1 | 2018 | 125 | 0.040 |
Why?
| | Cadherins | 1 | 2018 | 175 | 0.040 |
Why?
| | Porosity | 1 | 2016 | 93 | 0.030 |
Why?
| | Cell Count | 2 | 2010 | 304 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2018 | 4449 | 0.030 |
Why?
| | Equipment Design | 1 | 2018 | 516 | 0.030 |
Why?
| | Snail Family Transcription Factors | 1 | 2016 | 20 | 0.030 |
Why?
| | Smad3 Protein | 1 | 2016 | 41 | 0.030 |
Why?
| | Smad2 Protein | 1 | 2016 | 34 | 0.030 |
Why?
| | Smad4 Protein | 1 | 2016 | 34 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2018 | 934 | 0.030 |
Why?
| | Fibrosis | 1 | 2018 | 455 | 0.030 |
Why?
| | Biomimetic Materials | 1 | 2016 | 64 | 0.030 |
Why?
| | Registries | 1 | 2023 | 1773 | 0.030 |
Why?
| | Medication Errors | 1 | 2015 | 89 | 0.030 |
Why?
| | HeLa Cells | 1 | 2016 | 568 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2016 | 346 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 868 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 2814 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1374 | 0.030 |
Why?
| | Cattle | 1 | 2016 | 935 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2018 | 1970 | 0.030 |
Why?
| | In Situ Nick-End Labeling | 2 | 2003 | 119 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2015 | 504 | 0.030 |
Why?
| | Blotting, Western | 2 | 2005 | 1153 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2018 | 2196 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2018 | 3916 | 0.020 |
Why?
| | Corneal Diseases | 1 | 2010 | 34 | 0.020 |
Why?
| | Immunohistochemistry | 2 | 2005 | 1643 | 0.020 |
Why?
| | Organ Size | 1 | 2010 | 435 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2018 | 2362 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2010 | 678 | 0.020 |
Why?
| | Ultrasonography | 1 | 2010 | 671 | 0.020 |
Why?
| | Molteno Implants | 1 | 2006 | 2 | 0.020 |
Why?
| | Nerve Crush | 1 | 2005 | 6 | 0.020 |
Why?
| | Depression, Chemical | 1 | 2005 | 23 | 0.020 |
Why?
| | Calcineurin | 1 | 2005 | 84 | 0.020 |
Why?
| | Prosthesis Design | 1 | 2006 | 290 | 0.010 |
Why?
| | Apoptosis | 2 | 2003 | 2377 | 0.010 |
Why?
| | Time Factors | 2 | 2005 | 6186 | 0.010 |
Why?
| | Caspase 7 | 1 | 2003 | 22 | 0.010 |
Why?
| | Enzyme Precursors | 1 | 2002 | 15 | 0.010 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2003 | 88 | 0.010 |
Why?
| | Retina | 1 | 2005 | 269 | 0.010 |
Why?
| | Staining and Labeling | 1 | 2002 | 139 | 0.010 |
Why?
| | Immunoblotting | 1 | 2002 | 283 | 0.010 |
Why?
| | Caspase 3 | 1 | 2003 | 237 | 0.010 |
Why?
|
|
Pantcheva's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|